Search clinical trials for: IDP-108

Total 6806 results

PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia
Dow Pharmaceutical Sciences

Completed

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

Onychomycosis

Mexico
Dow Pharmaceutical Sciences

Completed

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Onychomycosis

United States, Canada
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Onychomycosis

United States, Canada, Japan
Dow Pharmaceutical Sciences

Unknown

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 (IDP-118)

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Dow Pharmaceutical Sciences

Completed

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Dow Pharmaceutical Sciences

Completed

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Acne Vulgaris

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Psoriasis

United States
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

Psoriasis

United States
InQpharm Group

Completed

Benefit and Tolerability of IQP-AE-103 in Weight Loss

Obesity | Overweight

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Heidelberg Pharma AG

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Multiple Myeloma | Plasma Cell Disorder

United States, Germany, Poland, Hungary
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

Study of ICP-105 in Solid Tumors Patients

Solid Tumor

China
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
InQpharm Group

Completed

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

Appetite Regulation | Energy Intake | Appetite Suppression

Germany
InQpharm Group

Completed

Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

Hyperglycemia | Prediabetes

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany
InQpharm Group

Withdrawn

Vasoactive Effects of IQP-AS-118 in Healthy Individuals

Cardiovascular Disease | Blood Flow

Germany
InQpharm Group

Completed

Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol

Blood Pressure | Low Density Lipoprotein Cholesterol Level

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP- AK-102 in Reducing Body Weight

Weight Loss

Germany
InQpharm Group

Terminated

Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections

Common Cold | Upper Respiratory Tract Infections

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-AK-102 in Reducing Appetite

Weight Loss | Appetite Modulation (Focus of Study)

Germany
Perrigo CSCI
Analyze & Realize

Completed

DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

Obesity | Overweight

Germany
InQpharm Group

Completed

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Dentin Sensitivity

Germany
InQpharm Group
Analyze & Realize

Completed

Benefit of IQP-AO-101 for Sleep

Insomnia, Nonorganic

Germany
InQpharm Group

Completed

Efficacy and Safety of IQP-VV-102 in Weight Management

Obesity | Overweight

Germany
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
Bausch Health Americas, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Colorectal Cancer

Japan
InQpharm Group

Completed

Benefit and Tolerability of IQP-LU-104 in Weight Loss

Obesity | Overweight

Germany
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Transwell Biotech Co., Ltd.

Completed

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

Diabetic Foot Ulcer

Taiwan
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

Atopic Dermatitis

United States
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Atopic Dermatitis

United States
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Acne Vulgaris

United States, Canada

3

Subscribe